4-[2-Fluoro-4-[(2-fluoro-4-methylsulfonylphenoxy)methyl]cyclohexyl]piperazine-1-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-[2-Fluoro-4-[(2-fluoro-4-methylsulfonylphenoxy)methyl]cyclohexyl]piperazine-1-carboxylic acid
• 英文别名: 4-[2-fluoro-4-[(2-fluoro-4-methylsulfonylphenoxy)methyl]cyclohexyl]piperazine-1-carboxylic acid
• 化学式: C₁₉H₂₆F₂N₂O₅S
• 分子量: 432.5
• InChiKey: VKAMKVPSPZACOF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  95.5
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
  申请人：Jones Robert M.

  公开号：US20140066369A1

  公开（公告）日：2014-03-06

  The present invention relates to compounds of Formula I and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as single pharmaceutical agents or in combination with one or more additional pharmaceutical agents, such as, a DPP-IV inhibitor, a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an SGLT2 inhibitor, a meglitinide, a thiazolidinedione, or an anti-diabetic peptide analogue, in the treatment of for example, a disorder selected from: a GPR119-receptor-related disorder; a condition ameliorated by increasing a blood incretin level; a condition characterized by low bone mass; a neurological disorder; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto.

  本发明涉及式I化合物及其药学上可接受的盐、溶剂和水合物，它们可作为单一药物或与一个或多个其他药物联合使用，例如DPP-IV抑制剂、双胍类药物、α-葡萄糖苷酶抑制剂、胰岛素类似物、磺脲类药物、SGLT2抑制剂、噻唑烷二酮类药物或抗糖尿病肽类似物，用于治疗选择性疾病，例如GPR119受体相关疾病、通过增加血液肠促素水平改善的病症、低骨量的病症、神经系统疾病、代谢相关疾病、2型糖尿病、肥胖及其相关并发症。